Stonebridge Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Stonebridge Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-121	Closed	-$42.1K	–	844
2023 Q3	$42.1K	Hold	121	–	–	﹤0.01%	383
2023 Q2	$42.6K	Buy	+121	New	+$40.8K	﹤0.01%	393
2023 Q1	–	Sell	-32	Closed	-$9.24K	–	1008
2022 Q4	$9.24K	Sell	32 -1	-3%	-$305	﹤0.01%	610
2022 Q3	$10K	Sell	33 -94	-74%	-$27K	﹤0.01%	581
2022 Q2	$36K	Hold	127	–	–	﹤0.01%	402
2022 Q1	$33K	Hold	127	–	–	﹤0.01%	453
2021 Q4	$28K	Hold	127	–	–	﹤0.01%	458
2021 Q3	$23K	Hold	127	–	–	﹤0.01%	468
2021 Q2	$26K	Buy	+127	New	+$26.6K	﹤0.01%	454
2020 Q1	–	Sell	-9	Closed	-$2K	–	865
2019 Q4	$2K	Buy	+9	New	+$1.82K	﹤0.01%	756

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Stonebridge Capital Advisors's VRTX Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 121 shares — an estimated $42.1K sold.

Stonebridge Capital Advisors first reported a position in VRTX in Q4 2019 and held it in 10 quarters. The position peaked at $42.6K in Q2 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 121 Vertex Pharmaceuticals shares in Q4 2023, an estimated $42.1K.
Stonebridge Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Stonebridge Capital Advisors's Vertex Pharmaceuticals position peaked at $42.6K in Q2 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.